CN Patent

CN121175051A — 氘代鲁索替尼（deuruxolitinib）的结晶形式

Assigned to Sun Pharmaceutical Industry Co ltd · Expires 2025-12-19 · 0y expired

What this patent protects

本公开涉及(βR)‑β‑(环戊基‑2,2,3,3,4,4,5,5‑d 8 )‑4‑(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)‑1H‑吡唑‑1‑丙腈磷酸盐(1:1)(氘代鲁索替尼磷酸盐(deuruxolitinib phosphate))的多晶型物形式1。还公开了使用氘代鲁索替尼磷酸盐的多晶型物形式1的治疗方法和产生氘代鲁索替尼磷酸盐的多晶型物形式1的方法。

USPTO Abstract

本公开涉及(βR)‑β‑(环戊基‑2,2,3,3,4,4,5,5‑d 8 )‑4‑(7H‑吡咯并[2,3‑d]嘧啶‑4‑基)‑1H‑吡唑‑1‑丙腈磷酸盐(1:1)(氘代鲁索替尼磷酸盐(deuruxolitinib phosphate))的多晶型物形式1。还公开了使用氘代鲁索替尼磷酸盐的多晶型物形式1的治疗方法和产生氘代鲁索替尼磷酸盐的多晶型物形式1的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN121175051A
Jurisdiction
CN
Classification
—
Expires
2025-12-19
Drug substance claim
No
Drug product claim
No
Assignee
Sun Pharmaceutical Industry Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.